Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
暂无分享,去创建一个
T. Yamanaka | H. Kirikoshi | A. Nakajima | M. Taguri | M. Yoneda | S. Saito | Y. Ogawa | Y. Honda | Takaomi Kessoku | K. Imajo | Asako Nogami | T. Iwasaki | Takashi Kobayashi | Anna Ozaki | T. Kurihashi | Kento Imajo | Yuji Ogawa | Takeo Kurihashi
[1] K. Cusi,et al. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease , 2020, Current Diabetes Reports.
[2] M. Cowie,et al. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control , 2020, Nature Reviews Cardiology.
[3] M. Packer. Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes. , 2020, Journal of diabetes and its complications.
[4] C. Mathieu,et al. Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD) , 2020, Diabetologia.
[5] K. Cusi. A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[6] B. Neuschwander‐Tetri,et al. Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASH , 2020, Hepatology.
[7] Seoyoung C. Kim,et al. Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes , 2020, Annals of Internal Medicine.
[8] T. Yamanaka,et al. Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study) , 2019, Contemporary clinical trials communications.
[9] C. Mathieu,et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2019, Diabetes Care.
[10] Yangang Wang,et al. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. , 2019, The Journal of clinical endocrinology and metabolism.
[11] N. Stefan,et al. Diabetes and Fatty Liver. , 2019, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[12] N. Stefan,et al. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial , 2019, Diabetes Care.
[13] K. Cusi,et al. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.
[14] D. Giugliano,et al. Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials , 2019, Journal of the American Heart Association.
[15] V. Wong,et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. , 2019, The lancet. Gastroenterology & hepatology.
[16] K. Cusi,et al. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. , 2019, The lancet. Diabetes & endocrinology.
[17] K. Murotani,et al. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective, single‐arm trial (LEAD trial) , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.
[18] S. Mudaliar,et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes , 2019, Diabetes, obesity & metabolism.
[19] T. Yamanaka,et al. Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non‐alcoholic fatty liver disease , 2018, Journal of gastroenterology and hepatology.
[20] L. Lind,et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study , 2018, Diabetologia.
[21] A. Mithal,et al. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial) , 2018, Diabetes Care.
[22] J. Talwalkar,et al. When and how to use magnetic resonance elastography for patients with liver disease in clinical practice , 2018, The American Journal of Gastroenterology.
[23] Michael Charlton,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[24] K. Murotani,et al. Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein levels and liver fibrosis: A meta‐analysis , 2017, Journal of gastroenterology and hepatology.
[25] P. Aschner. F1000Prime recommendation of Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. , 2017 .
[26] Rohit Loomba,et al. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. , 2017, Gastroenterology.
[27] S. Takeishi,et al. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study. , 2017, Endocrine journal.
[28] M. Noda,et al. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial , 2017, Diabetes Care.
[29] Lingling He,et al. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials , 2016, Medicine.
[30] E. Gronda,et al. Glucagon and heart in type 2 diabetes: new perspectives , 2016, Cardiovascular Diabetology.
[31] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[32] E. Ferrannini,et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis , 2016, Diabetes Care.
[33] Jonathan Rubin,et al. Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement , 2016, Ultrasound quarterly.
[34] V. Perkovic,et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. , 2016, The lancet. Diabetes & endocrinology.
[35] T. Yamanaka,et al. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. , 2016, Gastroenterology.
[36] K. Cusi,et al. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes , 2016, Diabetes Care.
[37] European Association for the Study of the Liver,et al. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.
[38] T. Saibara,et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2015, Journal of Gastroenterology.
[39] H. Yki-Järvinen. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.
[40] A. Gamst,et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. , 2013, Radiology.
[41] Enzo Bonora,et al. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.
[42] C. Bailey,et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.
[43] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[44] C. Pollock,et al. Renal glucose transporters: novel targets for hyperglycemia management , 2010, Nature Reviews Nephrology.
[45] A. Feldstein,et al. Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study , 2009, Hepatology.
[46] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[47] J. Hardies,et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. , 2002, The Journal of clinical endocrinology and metabolism.
[48] T. Saruta,et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. , 2002, Metabolism: clinical and experimental.